Mepolizumab – Medxy AI

Switching from Mepolizumab to Benralizumab in EGPA: A Promising Alternative for Persistent Respiratory Symptoms

By MedXY 10/23/2026

In EGPA patients unresponsive to mepolizumab, switching to benralizumab improves lung function, reduces glucocorticoid use, and shows a favorable safety profile, suggesting its potential as an effective alternative treatment.

news Respiratory

Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment Comparison

By MedXY 08/23/2026

A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.

news Respiratory

Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy

By MedXY 06/13/2026

This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.

Allergy & Immunology news Pediatrics Respiratory

Unveiling Diverse Inflammatory Pathways in Residual Pediatric Asthma Exacerbations Under Mepolizumab Therapy

By MedXY 10/27/2025

This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammation.

news Respiratory

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

By MedXY 09/19/2025

Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.